Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06458036 · ClinicalTrials.gov registry record · Phase 2
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
A Phase 2 study of Cancer and Pediatric Cancer, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 2
- Study locations
NCT06458036 is a Phase 2 study of Cancer and Pediatric Cancer that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 13 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06458036, a Phase 2 study of Cancer and Pediatric Cancer, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 2
- Study locations
Study Summary
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.
Conditions Studied
Interventions
- DRUG Selpercatinib Monotherapy
- RADIATION 131I Therapy
Study Locations (2)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2024-07-29 |
| Est. Completion | 2031-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06458036
The ClinicalTrials.gov registry entry for NCT06458036 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Selpercatinib Monotherapy is the first listed.
NCT06458036 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06458036 about?
NCT06458036 is a clinical study titled "Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)". Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve ...
What is the current status of trial NCT06458036?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2024-07-29. Estimated completion is 2031-11-01.
What conditions does trial NCT06458036 study?
This clinical trial studies the following conditions: Cancer, Pediatric Cancer, Differentiated Thyroid Cancer, Cancer, Thyroid.
What interventions are being tested in trial NCT06458036?
The interventions under investigation include: Selpercatinib Monotherapy (DRUG), 131I Therapy (RADIATION).
Who is sponsoring clinical trial NCT06458036?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06458036 being conducted?
This trial has 2 study locations across Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.